Wellington Management Group LLP Has $407 Million Position in Vaxcyte, Inc. $PCVX

Wellington Management Group LLP lifted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 24.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,001,565 shares of the company’s stock after acquiring an additional 1,386,968 shares during the period. Wellington Management Group LLP owned approximately 4.71% of Vaxcyte worth $407,001,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Jupiter Topco LLC acquired a new position in Vaxcyte during the second quarter valued at approximately $1,044,355,000. BlackRock Inc. acquired a new stake in shares of Vaxcyte in the 2nd quarter valued at $701,520,000. Janus Henderson Group PLC boosted its holdings in shares of Vaxcyte by 23.8% in the 1st quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock valued at $960,231,000 after purchasing an additional 3,188,687 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of Vaxcyte by 35.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock valued at $521,213,000 after purchasing an additional 2,981,038 shares during the last quarter. Finally, Caligan Partners LP acquired a new position in shares of Vaxcyte during the 4th quarter worth $78,660,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on PCVX shares. Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Finally, Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $86.00.

Vaxcyte Stock Down 2.2%

Shares of PCVX opened at $59.83 on Friday. The stock has a market cap of $8.90 billion, a PE ratio of -7.84 and a beta of 1.23. Vaxcyte, Inc. has a 12-month low of $30.32 and a 12-month high of $65.00. The business has a 50-day simple moving average of $57.48 and a two-hundred day simple moving average of $55.99.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same period last year, the business earned ($1.22) EPS. On average, equities research analysts expect that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Insider Buying and Selling at Vaxcyte

In related news, CFO Andrew Guggenhime sold 10,000 shares of Vaxcyte stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $57.28, for a total transaction of $572,800.00. Following the sale, the chief financial officer directly owned 104,395 shares in the company, valued at $5,979,745.60. This trade represents a 8.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $49.52, for a total transaction of $111,420.00. Following the sale, the chief operating officer directly owned 158,494 shares in the company, valued at $7,848,622.88. The trade was a 1.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 120,646 shares of company stock worth $6,570,810 in the last 90 days. Corporate insiders own 3.30% of the company’s stock.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.